Misplaced Pages

MYK-224

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.

References

  1. Lehman, Sarah J.; Crocini, Claudia; Leinwand, Leslie A. (June 2022). "Targeting the sarcomere in inherited cardiomyopathies". Nature Reviews Cardiology. 19 (6): 353–363. doi:10.1038/s41569-022-00682-0. ISSN 1759-5010. PMC 9119933. PMID 35304599.
  2. Sebastian, Sneha Annie; Padda, Inderbir; Lehr, Eric J.; Johal, Gurpreet (September 2023). "Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy". American Journal of Cardiovascular Drugs. 23 (5): 519–532. doi:10.1007/s40256-023-00599-0. PMID 37526885. S2CID 260348901.
  3. Packard, Elizabeth; de Feria, Alejandro; Peshin, Supriya; Reza, Nosheen; Owens, Anjali Tiku (December 2022). "Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy". Cardiology and Therapy. 11 (4): 491–507. doi:10.1007/s40119-022-00283-5. PMC 9652179.
Categories: